

FOI 1751

10th July 2023

FREEDOM OF INFORMATION ACT 2000 – INFORMATION REQUEST

Q1. How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies?

Abemaciclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)	6
Abemaciclib + Fulvestrant	<5
Alpelisib + Fulvestrant	0
Anthracycline (e.g. doxorubicin or epirubicin) as a single agent	0
Atezolizumab +Nab-paclitaxel/Paclitaxel	<5
Capecitabine as a single agent	<5
Capecitabine with denosumab	<5
Eribulin as a single agent or in combination	0
Everolimus + Exemestane	0
Fulvestrant as a single agent	Information not held
Lapatinib	0
Neratinib	0
Parp Inhibitors (Olaparib/Talazoparib	<5
Palbociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole) – palbociclib alone	7
Palbociclib and densoumab	12
Palbociclib and goserelin	<5
Palbociclib, goserelin and denosumab	<5
Palbociclib + Fulvestrant	<5
Pembrolizumab	0
Platinum (e.g. carboplatin or cisplatin) as a single agent	<5
Ribociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)	<5
Ribociclib and denosumab	<5
Ribociclib and goserelin	<5
Ribociclib + Fulvestrant	<5
Sacituzumab Govitecan	<5
Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent	<5
Taxane and/or Anthracycline in combination	27
Trastuzumab as a single agent or in combination	30
Trastuzumab emtansine	6
Transtuzumab deruxtecan	<5

Any other active systemic anti-cancer therapy?

Capecitabine, tucatinib and Herceptin	<5
Vinorelbine oral	<5

Q2. Does your trust participate on any clinical trials for the treatment of breast cancer? If so, please provide the name of each trial and the number of patients taking part.

No

The Trust has a legal duty to protect patient confidentiality and, in line with this duty, the figure <5 has been provided where figures are very low. This is because of the potential risk of identification of an individual. In reaching this decision the Trust has taken into account the small geographical area which the Trust serves and the sensitivity of the information requested. In addition the Trust has taken into account the fact that all information disclosed in response to an FOI is disclosed to the 'world at large' and is published on the Trust website.

S 40 (2) (third party information) of the Freedom of Information Act 2000 has been applied to exempt the redacted information from disclosure. The Trust does not consider the disclosure of the redacted information to be fair to the individuals concerned as there is the potential risk of identification of an individual(s) which they would not expect, and which would therefore breach the fairness element of the first principle of the Data Protection Act 2018.

Contact: FOI.team@southerntrust.hscni.net